CL2020002105A1 - Marcadores de la enfermedad de farber y usos de estos. - Google Patents
Marcadores de la enfermedad de farber y usos de estos.Info
- Publication number
- CL2020002105A1 CL2020002105A1 CL2020002105A CL2020002105A CL2020002105A1 CL 2020002105 A1 CL2020002105 A1 CL 2020002105A1 CL 2020002105 A CL2020002105 A CL 2020002105A CL 2020002105 A CL2020002105 A CL 2020002105A CL 2020002105 A1 CL2020002105 A1 CL 2020002105A1
- Authority
- CL
- Chile
- Prior art keywords
- farber
- markers
- disease
- diagnosis
- treatment
- Prior art date
Links
- 208000001948 Farber Lipogranulomatosis Diseases 0.000 title abstract 3
- 238000003745 diagnosis Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
- C12Y305/01023—Ceramidase (3.5.1.23)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Obesity (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Se describen marcadores de inmunofenotipo para la enfermedad de Farber y sus usos, al igual que los métodos de diagnóstico y tratamiento de la enfermedad de Farber basados en estos marcadores.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862648775P | 2018-03-27 | 2018-03-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020002105A1 true CL2020002105A1 (es) | 2020-12-04 |
Family
ID=66530353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020002105A CL2020002105A1 (es) | 2018-03-27 | 2020-08-14 | Marcadores de la enfermedad de farber y usos de estos. |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP3775924A1 (es) |
| JP (2) | JP2021516757A (es) |
| KR (2) | KR20200136367A (es) |
| CN (2) | CN118112249A (es) |
| AU (1) | AU2019244477A1 (es) |
| BR (1) | BR112020016435A2 (es) |
| CA (1) | CA3090354A1 (es) |
| CL (1) | CL2020002105A1 (es) |
| CO (1) | CO2020010043A2 (es) |
| IL (2) | IL311212A (es) |
| MX (1) | MX2020008377A (es) |
| PH (1) | PH12020551206A1 (es) |
| RU (1) | RU2020119065A (es) |
| SG (1) | SG11202007508TA (es) |
| WO (1) | WO2019186272A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220088158A1 (en) * | 2019-01-23 | 2022-03-24 | Aceragen, Inc. | Method of ameliorating a pro-inflammatory immunophenotype in farber disease subjects by repeated administration of a recombinant human acid ceramidase |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5059421A (en) | 1985-07-26 | 1991-10-22 | The Liposome Company, Inc. | Preparation of targeted liposome systems of a defined size distribution |
| US5631237A (en) | 1992-12-22 | 1997-05-20 | Dzau; Victor J. | Method for producing in vivo delivery of therapeutic agents via liposomes |
| DE69407292T2 (de) | 1993-06-30 | 1998-06-25 | Genentech Inc | Verfahren zur herstellung von liposomen |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US5643599A (en) | 1995-06-07 | 1997-07-01 | President And Fellows Of Harvard College | Intracellular delivery of macromolecules |
| CA2905449A1 (en) * | 2013-03-14 | 2014-10-02 | Icahn School Of Medicine At Mount Sinai | Therapeutic acid ceramidase compositions and methods of making and using them |
| EP3115786A1 (en) * | 2015-07-08 | 2017-01-11 | Centogene AG | Method for the diagnosis of farber's disease |
-
2019
- 2019-03-22 CA CA3090354A patent/CA3090354A1/en active Pending
- 2019-03-22 EP EP19723847.0A patent/EP3775924A1/en active Pending
- 2019-03-22 RU RU2020119065A patent/RU2020119065A/ru unknown
- 2019-03-22 IL IL311212A patent/IL311212A/en unknown
- 2019-03-22 KR KR1020207023065A patent/KR20200136367A/ko not_active Application Discontinuation
- 2019-03-22 WO PCT/IB2019/000290 patent/WO2019186272A1/en unknown
- 2019-03-22 SG SG11202007508TA patent/SG11202007508TA/en unknown
- 2019-03-22 JP JP2020543884A patent/JP2021516757A/ja active Pending
- 2019-03-22 CN CN202311688835.6A patent/CN118112249A/zh active Pending
- 2019-03-22 KR KR1020247022597A patent/KR20240111011A/ko active Search and Examination
- 2019-03-22 MX MX2020008377A patent/MX2020008377A/es unknown
- 2019-03-22 AU AU2019244477A patent/AU2019244477A1/en active Pending
- 2019-03-22 CN CN201980008575.9A patent/CN111971562A/zh active Pending
- 2019-03-22 BR BR112020016435-6A patent/BR112020016435A2/pt unknown
-
2020
- 2020-07-30 IL IL276420A patent/IL276420A/en unknown
- 2020-08-07 PH PH12020551206A patent/PH12020551206A1/en unknown
- 2020-08-14 CL CL2020002105A patent/CL2020002105A1/es unknown
- 2020-08-14 CO CONC2020/0010043A patent/CO2020010043A2/es unknown
-
2023
- 2023-08-03 JP JP2023127159A patent/JP2023159164A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RU2020119065A (ru) | 2022-04-27 |
| EP3775924A1 (en) | 2021-02-17 |
| CO2020010043A2 (es) | 2020-11-10 |
| CN118112249A (zh) | 2024-05-31 |
| IL311212A (en) | 2024-05-01 |
| WO2019186272A1 (en) | 2019-10-03 |
| JP2023159164A (ja) | 2023-10-31 |
| BR112020016435A2 (pt) | 2020-12-15 |
| KR20200136367A (ko) | 2020-12-07 |
| PH12020551206A1 (en) | 2021-04-19 |
| AU2019244477A1 (en) | 2020-06-25 |
| KR20240111011A (ko) | 2024-07-16 |
| MX2020008377A (es) | 2020-09-25 |
| CA3090354A1 (en) | 2019-10-03 |
| CN111971562A (zh) | 2020-11-20 |
| IL276420A (en) | 2020-09-30 |
| JP2021516757A (ja) | 2021-07-08 |
| SG11202007508TA (en) | 2020-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021003191A1 (es) | Inhibidores de tead y usos de los mismos | |
| CL2021003190A1 (es) | Inhibidores de tead y usos de los mismos | |
| CL2019003627A1 (es) | Anticuerpos anti-pd-1 y sus usos. (solicitud divisional 201900628) | |
| CO2021005987A2 (es) | Compuestos de anillo fusionado | |
| DOP2019000180A (es) | INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS | |
| CL2019001646A1 (es) | Anticuerpos anti-ox40 y sus usos. | |
| BR112019005595A2 (pt) | compostos e métodos para modulação de ido e tdo, e indicações para os mesmos | |
| CO2021013339A2 (es) | Degradadores de stat y usos de los mismos | |
| ECSP099619A (es) | Anticuerpos anti-robo4 y sus usos | |
| CL2021002503A1 (es) | Anticuerpos contra triptasa, composiciones de estos y usos de estos. (divisional de solicitud 201902251) | |
| CO2018008304A2 (es) | Compuestos antiproliferativos y sus composiciones farmacéuticas y usos | |
| CO2023006684A2 (es) | Anticuerpos contra sars-cov-2 y usos de los mismos | |
| CO2021004789A2 (es) | Piridazinonas y sus métodos de uso | |
| CO2022008662A2 (es) | Degradadores de smarca y usos de los mismos | |
| CO2020015747A2 (es) | Analogos de rapamicina y usos de los mismos | |
| CO2023014770A2 (es) | Degradadores de cdk2 y sus usos | |
| CL2017002689A1 (es) | Derivados de pirrolidincarboxamido y métodos para prepararlos y usarlos | |
| CO2021014768A2 (es) | Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares | |
| CO2020006907A2 (es) | Péptidos antimicrobianos y métodos para usarlos | |
| ECSP20016817A (es) | Sistemas y métodos para el control de la enfermedad de necrosis hepatopancreática aguda | |
| CL2015003563A1 (es) | Marcador para trastornos de la esfingomielinasa ácida y sus usos. | |
| AR121390A1 (es) | Composiciones y métodos para tratar la deficiencia auditiva no relacionada con la edad en un sujeto humano | |
| ECSP22019177A (es) | Proteínas de fusión nkg2d y sus usos | |
| CL2020002105A1 (es) | Marcadores de la enfermedad de farber y usos de estos. | |
| CO2022003324A2 (es) | Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares |